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Abstract
Salsolinol (6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline), widely available in many edibles, is considered to alter the
function of dopaminergic neurons in the central nervous system and thus, multiple hypotheses on its either physiological and/or
pathophysiological role have emerged. The aim of our work was to revisit its potentially neurotoxic and/or neuroprotective role
through a series of both in vitro and in vivo experiments. Salsolinol in the concentration range 10–250 μM did not show any
significant release of lactate dehydrogenase from necrotic SH-SY5Y cells and was able in the concentration of 50 and 100 μM to
rescue SH-SY5Y cells from death induced by H2O2. Its neuroprotective effect against neurotoxin 6-hydroxydopamine was also
determined. Salsolinol was found to decrease significantly the reactive oxygen species level in SH-SY5Y cells treated by 500 μM
H2O2 and the caspase activity induced by 300 μM of H2O2 or 100 μM of 6-hydroxydopamine. Serum levels of TNFα and CRP
of salsolinol-treated rats were not significantly different from control animals. Both TNFα and CRP served as indirect markers of
neurotoxicity and/or neuroprotection. Although the neurotoxic properties of salsolinol have numerously been emphasized, its
neuroprotective properties should not be neglected and need greater consideration.
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Introduction
The tetrahydroisoquinoline skeleton is encountered in a num-
ber of bioactive compounds. Tetrahydroisoquinoline deriva-
tives may be formed endogenously as metabolites of biogenic
amines (or their precursors) as well as be delivered exoge-
nously, directly from food. The tetrahydroisoquinoline family,
widespread in nature, can be divided into compounds with
catechol- and non-catechol structure. The simplest representa-
tive of non-catechol tetrahydroisoquinolines, 1,2,3,4-
tetrahydroisoquinoline, occurs naturally in plants (Makino
et al. 1988; Niwa et al. 1989) as well as in the brain of humans,
primates, and rodents (Makino et al. 1990; Niwa et al. 1987,
1993; Yamakawa et al. 1999, Yamakawa and Ohta 1999).
Catechol derivatives include, among others, salsolinol (6,7-
dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline; molecu-
lar weight 179.219 g/mol), which is usually considered as a
neurotoxin with the ability to alter the function of dopaminer-
gic neurons and dopamine metabolism in the central nervous
system. It wasMaruyama et al. (1995) who first suggested that
salsolinol might in fact possess both neurotoxic and neuropro-
tective activity. Salsolinol possesses an asymmetric center at
C-1 and thus, it exists as R and S enantiomers, with the
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predominance of (R)-salsolinol in human brain tissue (Deng
et al. 1997; Musshoff et al. 1999, 2000, 2003, 2005). So far,
numerous hypotheses on the physiological or pathophysiolog-
ical role of salsolinol have emerged, mostly with regard to
salsolinol as (1) a modulator of catecholaminergic neurotrans-
mission in the nigrostriatal pathway and possibly an etiologi-
cal factor in Parkinson’s disease (PD), (2) a neuromodulator in
the mesolimbic pathway related to reinforcing effects of alco-
hol consumption, and (3) a prolactin-releasing factor in the
tuberoinfundibular pathway. Yet, its neuromodulatory role is
rather poorly understood, lacks detail, and remains
inconclusive.
The aim of our work was to revisit the potential neurotoxic
and/or neuroprotective role of salsolinol through a series of
both in vitro (SH-SY5Y and IMR-32 human neuroblastoma
cell lines) and in vivo (male Wistar rats) experiments.
Materials and Methods
In Vitro Experiments
Cell Lines
SH-SY5Y (ATCC® CRL-2266™) cell line, a popular cell
model for PD research (Xie et al. 2010), was purchased from
ATCC (Manassas, VA, USA).
IMR-32 (ATCC® CCL-127™) cell line was provided by
the Department of Oncogenomics, Academisch Medisch
Centrum, Amsterdam, Holland. This cell line expresses most
of the proteins of cholinergic neurons and was described as an
in vitro model to study on Alzheimer’s disease (AD) (Neill
et al. 1994).
The cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM/F12) with 10% fetal bovine serum obtained
both from Gibco (Carlsbad, CA, USA) at 37 °C in an atmo-
sphere containing 5% of CO2.
Chemicals
(RS)-salsolinol (SAL), purity ≥ 99%, was obtained from
Cayman Chemica l (Ann Arbo r , MI , USA) . 6 -
Hydroxydopamine (6-OHDA), the commonly applied neuro-
toxin in experimental animal models of PD (Blum et al. 2001),
and 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Hydrogen peroxide (H2O2) was obtained from Synoptis
Pharma (Warsaw, Poland).
Lactate Dehydrogenase Test
CytoTox-ONE™ Homogeneous Membrane Integrity Assay
(LDH) was purchased from Promega (Madison, WI, USA).
SH-SY5Y or IMR-32 cells were seeded in 96-well white
plates with transparent bottom at a concentration of 2.5 ×
104 cells/well in 100 μl culture medium and cultured for
24 h to reach 70% confluence. For toxicity estimation, the
10 mM SAL stock solution in DMSO was diluted into fresh
culture medium and added into the microplates at the final
concentrations 10–250 μM. For neuroprotective studies, SH-
SY5Y cells were preincubated first for 1 h with SAL at the
final concentrations 100 and 250 μM and next 6-OHDA neu-
rotoxin was added at final concentration of 50 μM. The IMR-
32 cells were tested with SAL and 6-OHDA final concentra-
tions 100 μM and 200 μM, respectively. After 24 h of incu-
bation, the CytoTox-ONE™ was added to each well and cells
were incubated for 10 min at room temperature. Lysis solu-
tion, provided by the manufacturer, was also added to generate
a maximum lactate dehydrogenase (LDH) release control.
According to the protocol provided by the manufacturer the
Lysis solution was added 10 min before the measurement of
the fluorescence. Next, the fluorescence was measured using a
microplate reader EnSpire (PerkinElmer, Waltham, MA,
USA) with an excitation wavelength of 560 nm and an emis-
sion wavelength of 590 nm. All measurements were per-
formed in triplicate and results are shown as mean ± standard
deviation (SD).
Caspase Activity Assay
Apo-ONE® Homogeneous Caspase-3/7 Assay was pur-
chased from Promega (Madison, WI, USA). SH-SY5Y cells
were seeded in 384-well black plates with transparent bottom
at a concentration of 1 × 104 cells/well in 25 μl culture medi-
um and cultured for 24 h to reach 70% confluence. Cells were
preincubated first for 1 h with SAL at the final concentration
of 250 μM and next 6-OHDA or H2O2 were added at final
concentrations of 100 μMand 300 μM, respectively. After 6 h
of incubation, Apo-ONE® Homogeneous Caspase-3/7
Reagent was added to each well and cells were incubated for
18 h at room temperature, according to the manufacturer’s
protocol. The fluorescence of the samples was measured using
a microplate reader EnSpire (PerkinElmer, Waltham, MA
USA) with an excitation wavelength of 500 nm and an emis-
sion wavelength of 520 nm. All measurements were per-
formed in triplicate and results are shown as mean ± SD.
ROS Assay
SH-SY5Y cells were seeded in 96-well white plates with
transparent bottom at a concentration of 2.5 × 104 cells/well
in 100 μl culture medium and cultured for 24 h to reach 70%
confluence. Next, the old media were removed and cells were
preincubated first with DCFH-DA 250 μM solution in HBSS
buffer for 1 h. After DCFH-DA was removed, cells were
washed with HBSS and incubated next for 1 h with SAL at
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the final concentrations of 50, 100, and 250 μM in culture
media. Next, the H2O2 was added at final concentration 500
μM. After 3 h of incubation, the fluorescence was measured
using a microplate reader EnSpire (PerkinElmer, Waltham,
MAUSA) with an excitation wavelength of 486 nm and emis-
sion wavelength of 530 nm. All measurements were per-
formed in triplicate and results are shown as mean ± SD.
MTS Assay
The CellTiter 96® AQueous Non-Radioactive Cell
Proliferation Assay (MTS) was purchased from Promega
(Madison, WI, USA). SH-SY5Y cells were seeded in 96-
well transparent plates at a concentration of 2.5 × 104 cells/
well in 100 μl culture medium and cultured for 24 h to reach
70% confluence. The cells were preincubated first for 1 h with
SAL at the final concentrations 50 and 100 μMand next H2O2
was added at final concentration 300 μM. After 24 h of incu-
bation, the MTS labeling mixture was added to each well and
cells were incubated under the same conditions for 5 h. The
absorbance was measured using a microplate reader EnSpire
(PerkinElmer, Waltham, MA USA) at 490 nm. All measure-
ments were performed in triplicate and results are shown as
mean ± SD.
In Vivo Experiments
Adult male Wistar rats (Jagiellonian University Medical
College Animal Laboratory, Krakow, Poland) were housed
in individual transparent cages placed adjacent to each other
to provide sight, acoustic, and odor contact, with food and
water available ad libitum, temperature maintained at 23 ± 2
°C and under a 12:12-h dark/light cycle. Rats were fed a stan-
dard diet (protein 25%, fat 8%, carbohydrates 67%, 2.86
kcal/g, Labofeed B, Kcynia, Poland). After acclimatization
period, animals were randomly divided into the following
groups (n = 6 rats in each group): (1) continuous dosing of
SAL (purity ≥ 99%, Cayman Chemical, Ann Arbor, MI,
USA)—200 mg/kg in total with ALZET osmotic mini-
pumps (delivery rate 0.25 μL/h, Durect, USA) implanted in-
traperitoneally (i.p.) for 4 weeks (S1 group); (2) continuous
dosing of SAL—300 mg/kg in total with ALZET osmotic
mini-pumps implanted i.p. for 4 weeks (S2 group); (3) a con-
trol group (C group). SAL was dissolved in 0.9% NaCl.
Control rats received 0.9%NaCl.Mini-pumpswere implanted
under general anesthesia induced with sodium pentobarbital
given i.p. at a dose of 0.25 mg/kg (Vetbutal, Biowet, Poland).
All animal experiments were approved by the Jagiellonian
University Bioethical Committee (protocol number—67/
2009) and conducted in accordance with Good Laboratory
Practices.
General health status and motor function of the experimen-
tal animals were evaluated daily during handling and by
observing their in-cage behavior, including food intake and
body weight measurements. At the end of the experiment,
following 12 h overnight fasting, animals were euthanized
via decapitation and blood samples from the jugular vessels
were collected in plastic tubes and incubated at least 30 min at
4 °C to induce clot formation. After centrifugation at 1500×g
for 20 min at 4 °C (Megafuge 1.0R, Heraeus Instruments,
Germany), serum samples were collected and kept frozen at
− 80 °C until further analysis. Serum samples were assayed
for tumor necrosis factor–alpha (TNFα) (R&D Systems
Europe, Ltd. UK) and C-reactive protein (CRP, eBioscience,
Affymetrix, CA, USA) by ELISA method according to man-
ufacturer’s instructions. All measurements were performed in
duplicate and results are shown as mean ± SD.
Statistical Analysis
Statistical significances of in vitro data were evaluated by
GraphPad Prism™ software (version 5.01, San Diego, CA,
USA) using a one-way ANOVA, followed by Bonferroni’s
comparison test and are expressed as the mean ± standard
deviation (SD). In vivo results were analyzed by GraphPad
Prism™ software (version 7.0a, San Diego, CA, USA) using a
one-way analysis of variance (ANOVA) followed by a post
hoc Tukey’s test and are expressed as the mean ± SD.
Statistical significance was set at p < 0.05.
Results
In Vitro Tests—Cell Cultures (SH-SY5Y, IMR-32)
Together with Biochemical Assays (LDH Test, Caspase
Activity, ROS, and MTS)
The toxicity of SAL against human dopaminergic neuroblas-
toma SH-SY5Y (Xie et al. 2010) as well as cholinergic neu-
roblastoma IMR-32 (Neill et al. 1994) cell lines was examined
first by the LDH assay. The 24 h incubation of cells with (RS)-
salsolinol (SAL) in the concentration range 10–250 μM did
not show any statistically significant increased release of LDH
from necrotic cells (Fig. 1a, b) in comparison with the nega-
tive (vehicle, 1% DMSO in cell culture media) and positive
(total lysis reagent) controls.
The studies on potential neuroprotective activity of SAL
were performed next with use of 6-OHDA. The SH-SY5Y
cells were exposed to 6-OHDA at the concentration 50 μM
for 24 h with or without the presence of SAL in various con-
centrations (Fig. 2a). As result, the statistically significant (p <
0.001) decrease in LDH release in 6-OHDA injured cells was
observed in cells treated simultaneously by SAL in all tested
concentrations. Similarly, SAL (100 μM) protected signifi-
cantly (p < 0.05) IMR-32 cells exposed to 200 μM of 6-
OHDA for 24 h (Fig. 2b).
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To confirm SAL neuroprotection properties, additional stud-
ies were performed for SH-SY5Y cells with use of 300 μM of
H2O2 as toxic agent. The cell viability was measured colorimet-
rically using standard MTS procedure. SH-SY5Y cells were
incubated with H2O2 in the presence of SAL at 50 and
100 μM for 24 h. As shown in Fig. 3, MTS assay showed
statistically significant (p < 0.01, p < 0.001) increase in viability
of cells treated with H2O2 and SAL in comparisonwith the cells
treated H2O2 alone (positive control).
The SAL capability to reduce the ROS level and caspase
activity in cells injured by toxins was estimated next to eluci-
date its potential mechanism of neuroprotection. To measure
the effect of SAL on caspases 3/7 expression in 6-OHDA-
induced apoptosis, SH-SY5Y cells were incubated with 6-
OHDA (100 μM) for 6 h. Cytoplasmic caspase-3/7 activity
was then measured fluorometrically using the Apo ONE®
Homogeneous Caspase-3/7 Assay. The cells treated with 6-
OHDA and SAL at 250 μM showed statistically significant (p
< 0.01) reduction in 6-OHDA-induced caspase activity (Fig.
4). The similar test was performed with use of 300 μM of
H2O2 as an apoptosis inductor. The statistically significant (p
< 0.001) reduction in H2O2-induced caspase-3/7 activity in the
presence of SAL at 250 μM was also observed (Fig. 4).
To examine the effect of SAL on intracellular ROS reduc-
tion, the SH-SY5Y cells were incubated with H2O2 500 μM
for 3 h. The ROS level was measured using 2 ′,7 ′-
dichlorodihydrofluorescein diacetate (DCFH-DA), which in
the presence of ROS is oxidized to the highly fluorescent
dichlorofluorescein (DCF). As shown in Fig. 5, cells treated
with SAL at 50, 100, and 250 μM concentrations showed
statistically significant (p < 0.001) reduction in ROS level
(up to the negative control level) induced by 500 μM H2O2.
Fig. 2 The effect of (RS)-salsolinol (SAL) on lactate dehydrogenase
(LDH) release in SH-SY5Y neuroblastoma cells damaged by 50 μM 6-
hydroxydopamine (6-OHDA) at 24 h (a). The effect of (RS)-salsolinol
(SAL) on lactate dehydrogenase (LDH) release in IMR-32 neuroblastoma
cells damaged by 200 μM 6-hydroxydopamine (6-OHDA) at 24 h (b).
Statistical significance was set at ∗∗∗p < 0.001 and ∗p < 0.05 in compar-
ison with the positive controls (6-OHDA 50 μM for SH-SY5Y cells and
6-OHDA 200 μM for IMR-32 cells)
Fig. 1 Effect of (RS)-salsolinol
(SAL) on lactate dehydrogenase
(LDH) release in SH-SY5Y neu-
roblastoma cells (a). Effect of
(RS)-salsolinol (SAL) on lactate
dehydrogenase (LDH) release in
IMR-32 neuroblastoma cells (b)
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In Vivo Results—Behavioral Observations (General
Health Status, Motor Function, Food Intake and Body
Weight Measurements) Together with Biochemical
Analysis (TNFα and CRP)
None of the SAL-treated or control animals died or showed
any visible disturbances or discomfort to any significant de-
gree. No disturbance of gross motor function was observed in
any of the SAL-treated rats.
The total weight gain as well as the total weight gain over
the initial body weight was indistinguishable between the
SAL-treated groups; however, the total food intake was slight-
ly diminished in SAL-treated animals in comparison with the
control group of rats (Table 1).
TNFα serum levels were only significantly different be-
tween S1 and S2 groups (21.65 pg/ml ± 7.9 vs. 42.43 pg/ml ±
7.6, p = 0.029; C = 25.87 pg/ml ± 11.5), but were indistinguish-
able in SAL-treated rats in comparison with the control group
of rats. Changes in serum CRP levels were indistinguishable in
all SAL-treated groups in comparison with control animals and
showed similar trends to TNFα serum levels (S1 = 366 μg/ml,
S2 = 555 μg/ml vs. C = 470.9 μg/ml) (Fig. 6). Both TNFα and
CRP served as indirect markers of neurotoxicity and/or neuro-
protection and their use is justified by several publications
(Barcia et al. 2005; Tarrant 2010; Sawada et al. 2015;
Umemura et al. 2015; Qiu et al. 2019).
Discussion
Tetrahydroisoquinolines, including (RS)-salsolinol, are widely
distributed in the environment and can also be easily formed
endogenously from biogenic amines or amino acids. (RS)-
salsolinol is available in nano- to micromolar amounts per
gram in many edibles, such as fungi, vegetables, fruits, eggs,
and dairy or alcohol beverages (Collins et al. 1990;
DeCuypere 2010; Deng et al. 1997; Duncan et al. 1984;
Duncan and Smythe 1982; Melzig et al. 2000; Riggin et al.
1976; Riggin and Kissinger 1976; Smythe and Duncan 1985;
Strolin Benedetti et al. 1989a, b), see Table 2 for details.
Recently, Tuenter et al. (2018) revisited theMelzig hypoth-
esis (Melzig et al. 2000) about the role of (RS)-salsolinol in the
mood effects of cocoa. The D3-receptor is known to play a
role in the reward system and (RS)-salsolinol (especially S-
isomer) was found to bind to the receptor. It was hypothesized
that the amount of (RS)-salsolinol typically ingested by con-
suming about 100 g of dark chocolate (with 20–25 μg/g of
salsolinol racemate) was sufficient to reach a pharmacologi-
cally relevant concentration. According to Lee et al. (2010), in
the long term, (RS)-salsolinol from different dietary sources
Fig. 5 The effect of (RS)-salsolinol (SAL) on ROS level in SH-SY5Y
neuroblastoma cells treated by 500 μM H2O2 at 3 h. Statistical signifi-
cance was set at ∗∗∗p < 0.001, in comparison with the positive control
H2O2 (500 μM)
Fig. 4 The effect of (RS)-salsolinol (SAL) on the caspases 3/7 activity in
SH-SY5Y neuroblastoma cells damaged by 100μM6-hydroxydopamine
(6-OHDA) at 6 h. Statistical significance was set at ∗∗p < 0.001 in
comparison with the positive control (6-OHDA 100 μM), and ∗∗∗p <
0.001 in comparison with the positive control (H2O2 300 μM)
Fig. 3 The effect of (RS)-salsolinol (SAL) on SH-SY5Y neuroblastoma
cells viability damaged by 300 μM H2O2 at 24 h. Statistical significance
was set at ∗∗∗p < 0.001, ∗∗p < 0.01, in comparison with the positive
control H2O2 (300 μM)
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should be the major contributor to its plasma levels, both in
humans and rats. Yet, it remains unclear, whether it can cross
the blood-brain barrier to exert its central action (Origitano
et al. 1981; for a review, see Lee et al. 2010; Kurnik-Łucka
et al. 2018). In mammalian brain, (RS)-salsolinol is thought to
be formed via three mechanisms: (1) the nonenzymatic Pictet–
Spengler condensation of dopamine and aldehydes producing
salsolinol as two racemic isomers (R or S); (2) the non-
enzymatic condensation of dopamine and pyruvate yielding
1-carboxyl-tetrahydroisoquinoline, followed by decarboxyl-
ation and reduction, which produces (R)-salsolinol; (3) selec-
tive synthesis of (R)-salsolinol from dopamine and acetalde-
hyde by (R)-salsolinol synthase (Naoi et al. 2002).
Numerous in vitro experiments published so far suggest that
(RS)-salsolinol possesses mainly pro-apoptotic properties. The
human dopaminergic neuroblastoma SH-SY5Y cell line model
has been applied in majority of the studies with experimental
doses ranging up to 2.2 mM (for a review, see Kurnik-Łucka
et al. 2018). Foremostly, Morikawa et al. (1998) reported that
(RS)-salsolinol inhibited mitochondrial complex I activity;
however, its N-methylated derivatives or those with phenyl
group at the C1 position were more toxic to NADH-linked
respiration. ROS were increased and glutathione levels were
decreased when SH-SY5Y cells were treated with racemic
salsolinol, especially at concentrations near to 500 μM
(Wanpen et al. 2004). The treatment also decreased the levels
of an anti-apoptotic protein bcl-2 and increased a pro-apoptotic
protein bax (Shukla et al. 2013; Wanpen et al. 2007). Storch
et al. (2000) concluded that (RS)-salsolinol was toxic to human
dopaminergic neuroblastoma SH-SY5Y cells by blocking the
cellular energy supply via the inhibition of mitochondrial
complex II activity but not complex I. The rapid decrease in
the intracellular level of ATP and ATP/ADP ratio of intact cells
incubated with (RS)-salsolinol was dose- and time-dependent.
But it was Maruyama et al. (1995) who suggested that (RS)-
salsolinol and its derivatives might possess both neurotoxic and
neuroprotective activity. (R)-salsolinol and the 1,2-dimethyl-6,7-
dihydroxyisoquinolinium ion (40 and 200 μM) as well as N-
methyl-(R)-salsolinol (200 μM) reduced in vivo radical forma-
tion, with reduction of dopamine catabolism. (R)-salsolinol and
the 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion also reduced
in vitro hydroxyl radical production from dopamine autoxida-
tion. On the other hand, N-methyl-(R)-salsolinol (40 μM) in-
creased the hydroxyl radical level in the striatum, and the radical
production by its autoxidation was confirmed in vitro. Only
Możdżeń et al. (2015) confirmed biphasic effects of exogenous
(RS)-salsolinol. In rat hippocampal cell cultures, the lower in-
vestigated dose of (RS)-salsolinol (50 and 100 μM) diminished,
while its highest dose (500 μM) potentiated the glutamic acid
effect on caspase-3 activity. Similar effects were observed for
LDH release. In mouse striatum cultures, both the investigated
doses of (RS)-salsolinol (50 and 500 μM) revealed its neuropro-
tective activity. Authors concluded that exogenous salsolinol,
applied as a racemic mixture under physiological conditions,
should not be neurotoxic.
Our in vitro results suggest that the possible neuroprotective
properties of (RS)-salsolinol cannot indeed be neglected. First of
all, the used in our studies highly pure (≥ 99%), (RS)-salsolinol
in the concentration range 10–250 μM did not show any signif-
icant release of LDH from either necrotic SH-SY5Y cells (Fig.
1a) or necrotic IMR-32 cells (Fig. 1b). Moreover, a decrease in
LDH release in SH-SY5Y cells damaged by 50μMof 6-OHDA
Table 1 Total weight gain (g),
total weight gain over the initial
body weight (%), and total food
intake (g) in (RS)-salsolinol
(SAL)-treated (S1, S2) and the
control animals (C)
Group Total weight gain (g) Total weight gain over
initial body weight (%)
Total food intake (g)
S1 98.34 ± 31.61 39.4 ± 15.09 644.3 ± 56.9 (p < 0.05)
S2 103.25 ± 8.22 42.5 ± 4.6 585.0 ± 23.5 (p < 0.01)
C 120.36 ± 20.21 47.7 ± 12.7 696.9 ± 40.2
Statistical significance was set at ∗p < 0.05
Fig. 6 TNFα (a) and CRP (b)
serum levels in (RS)-salsolinol
(SAL)-treated (S1, S2) and con-
trol animals (C). Statistical sig-
nificance was set at ∗p < 0.05.
“Ns” refers to the lack of statisti-
cal significance
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was observed when treated together with (RS)-salsolinol in all
tested concentrations (Fig. 2a). Similarly, the presence of
100 μMof (RS)-salsolinol statistically significant decreased tox-
ic activity of 200 μM of 6-OHDA against IMR-32 cells (Fig.
2b). (RS)-salsolinol (50 and 100 μM) was also able to rescue
SH-SY5Y cells from death induced by 300 μM of H2O2 (Fig.
3). In ROS assay, SH-SY5Y cells treated with (RS)-salsolinol at
50, 100, and 250 μM concentrations showed a significant re-
duction in ROS level induced by 500 μMof H2O2 (Fig. 5). The
apoptosis of SH-SY5Y cells, estimated here as the increase in
caspase-3/7 activity induced by 100μMof 6-OHDAor 300μM
of H2O2, was also reduced significantly to the control level by
(RS)-salsolinol at 250 μM concentration. Moreover, no induc-
tion effect on caspase-3/7 activity by (RS)-salsolinol at 250 μM
itself was found (Fig. 4).
A question arises why these results significantly differ from
many others already published? The presence of two enantio-
mers and their origin, either endogenous or exogenous, is com-
plex. Most of the experimental data refer to exogenous (RS)-
salsolinol hydrochloride applied as a racemic mixture.
Quintanilla et al. (2014, 2016) not only chirally separated a com-
mercially available (RS)-salsolinol but also purified it from
isosalsolinol. Isosalsolinol is a by-product of non-enzymatical
Pictet–Spengler condensation, and at physiological pH, the reac-
tion of acetaldehyde and dopamine generates (RS)-salsolinol and
isosalsolinol in equal proportions, while under non-physiological
in vitro conditions (low pH), the synthesis of (RS)-salsolinol
predominates (Almodovar et al. 2017; Bates et al. 1986; King
et al. 1974). Variations in methodological approaches might be a
barrier to make an extensive summary. All in vitro studies should
be always interpreted with caution, since extrapolation of the
effects to humans is not straightforward.
From the chemical point of view, (RS)-salsolinol might
indeed possess neuroprotective properties due to the presence
of catechol (1,2-dihydroxybenzene) moiety. The relatively
high antioxidant activity of catechol can be explained by the
high electron-donating effect of one hydroxyl group to the
other (Fig. 7) (Heijnen et al. 2002, 2011). Indeed, the antiox-
idant properties of (RS)-salsolinol were confirmed here
in vitro, as it was able to reduce the H2O2-induced increase
in intracellular ROS level in SH-SY5Y cells (Fig. 5).
Moreover, taking into account the possible mechanisms of
6-OHDA toxicity, the antioxidant properties of (RS)-salsolinol
may be also responsible for determining here decrease of 6-
OHDA activity (Figs. 2 and 4). The mechanism of 6-OHDA
neurotoxicity was proposed to be the effect of increased level
of ROS derived from autoxidation and/or obtained by the 6-
OHDA biotransformation catalyzed by MAO-A (monoamine
oxidase A) (Rodriguez-Pallares et al. 2007; Simola et al.
2007). Thus, also, the inhibition of MAO activity by (RS)-
salsolinol (Fig. 7), which was first reported by Yamanaka
(1971), could also contribute to its neuroprotective properties.
The inhibition of 6-OHDA biotransformation catalyzed by
MAO-Amight decrease indirectly the intracellular ROS level,
which are the products of 6-OHDA catabolism (Meyerson
et al. 1976; Minami et al. 1993). Salsolinol, applied as a race-
mic mixture, inhibited MAO activity in the rat brainstem and
liver homogenates, and the inhibition was competitive to se-
rotonin, a substrate of MAO type A, and non-competitive to
benzylamine, a substrate of MAO type B (Meyerson et al.
1976). (R)-salsolinol inhibited MAO-A more potently than
the (S)-enantiomer in vitro (Minami et al. 1993). The results
were confirmed in vivo (Maruyama et al. 1993). The presence
of hydroxyl groups at the sixth and seventh positions and
substitution of a hydrogen group at the first position with a
methyl or dihydroxybenzyl group are to be required for the
inhibition, whereas the absence of a methyl group or presence
of a carboxyl group at the first position, in addition to a methyl
Table 2 Some examples of (RS)-salsolinol levels in different food products
Source Concentration range of
(RS)-salsolinol
Analytical method Reference
Banana Up to 40 ± 1,5 μg/g Liquid chromatography and thin-layer electrochemistry (Riggin et al. 1976)
Up to 537 μg/g Gas chromatography with mass spectrometry (Smythe and Duncan 1985)
Up to 50 μg/g High-performance liquid chromatography with
electrochemical detection
(Strolin Benedetti et al. 1989a)
709 nmol/g Ion-pair high-performance liquid chromatography
with beta-cyclodextrin
(Deng et al. 1997)
11.22 ± 0.049 μg/g Liquid chromatography–mass with tandem mass spectrometry (DeCuypere 2010)
Mushroom 21.92 ± 0.136 μg/g
Peach 14.29 ± 0.055 μg/g
Potato 0.52 ± 0.025 μg/g
Tomato 0.83 ± 0.049 μg/g
Bitter chocolate 1 μg/g High-performance liquid chromatography with
electrochemical detection
(Strolin Benedetti et al. 1989b)
Cacao Up to 25 μg/g Gas chromatography with mass spectrometry (Melzig et al. 2000)
Port wine Up to 488 nmol/l (Duncan and Smythe 1982)
4–85 ng/ml (Smythe and Duncan 1985)
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group, depletes the inhibitory activity (Bembenek et al. 1990;
Thull et al. 1995).
(RS)-salsolinol also competitively inhibited COMT (Fig. 7)
(Giovine et al. 1976). (RS)-salsolinol was O-methylated pri-
marily at the 7-position, to form salsoline (l-methyl-7-
methoxy-6-hydroxy-l,2,3,4-tetrahydroisoquinoline) (Collins
and Origitano 1983). Salsoline can be accumulated in cate-
cholamine nerve terminals of the brain and could act further as
a false neurotransmitter (Cohen and Mytilineou 1982). The
methylation of (S)-salsolinol should yield almost equivalent
amounts of the two possible 6- and 7-methyl ethers, whereas
the methylation of (R)-salsolinol should yield mostly (88%) 7-
O-methyl derivative (Hötzl and Thomas 1997). Still, accord-
i ng t o ex t en s i v e l i t e r a t u r e , 1 -me thy l - 1 , 2 , 3 , 4 -
tetrahydroisoquinoline (a non-catechol derivative) is regarded
as one of the most potent neuroprotectants among
tetrahydroisoquinolines in the brain (Fig. 7). Its neuroprotec-
tive effect did not induce the development of tolerance after
chronic administration and might restore the function of do-
pamine neurons (Antkiewicz-Michaluk et al. 2001; Wąsik
et al. 2016; Vetulani and Antkiewicz-Michaluk 2012; Peana
et al. 2019). 1-Methyl-1,2,3,4-tetrahydroisoquinoline did not
change the rate of total dopamine catabolism; it inhibited the
monoamine oxidase (MAO)-dependent catabolic pathway
and activated the catechol-O-methyltransferase (COMT)-de-
p e n d e n t O -m e t h y l a t i o n . 1 - B e n z y l - 1 , 2 , 3 , 4 -
tetrahydroisoquinoline, a compound considered as a highly
neurotoxic (Fig. 7) (Antkiewicz-Michaluk et al. 2001, 2013;
Yamakawa et al. 1999), produced the increase of the rate of
dopamine metabolism with strong activation of the oxidative
MAO-dependent catabolic pathway. It was also suggested that
larger substituents at C1 may increase the neurotoxicity of
tetrahydroisoquinolines (Wąsik et al. 2009).
Rodent models have been the most useful to study the oc-
currence, metabolism, and physiological function of (RS)-
salsolinol (and other tetrahydroisoquinolines). Unfortunately,
it is very difficult to pinpoint its exact physiological concentra-
tion since a whole array of chemically similar derivatives is
associated with dopamine metabolism in the central (and pe-
ripheral) nervous system. Nervous system in general exhibits a
great degree of cellular, structural, and chemical heterogeneity
and neurotoxins can potentially affect any of its functional or
structural components. So far, the neurotoxic properties of (RS)-
salsolinol have been mostly laid stress; however, there is no
agreement regarding its direct mechanism of action in the cen-
tral and/or peripheral nervous system and no agreement regard-
ing its ability to cross the blood-brain barrier either (Origitano
et al. 1981). And surely, a great variety in test methods is need-
ed to ensure its complete neurotoxicologic assessment. We de-
cided to measure serum levels of TNFα and CRP as blood-
based markers have the greatest potential for the translation of
preclinical risk assessment to the human patient population
(Tarrant 2010). TNFα is a major pro-inflammatory cytokine
that exerts both homeostatic and pathophysiological roles in
the central and peripheral nervous system. TNFα exerts its
action via two receptors, TNF-R1 and TNF-R2, which are
expressed in both glia and neurons. TNF-R1 is responsible for
controlling the neuronal death. TNF-R2 contributes to
1MeTIQ   SAL                  1BeTIQ
         DA     DA                            DA
        DOPAC        3MT    DOPAC    3MT              DOPAC             3MT
H2O2
         HVA    HVA              HVA
COMTCOMT COMTMAO MAO MAO
Fig. 7 Chemical structures and
the influence on the main
dopamine metabolic pathways of
1MeTIQ, SAL, and 1BeTIQ. DA
dopamine, DOPAC 3,4-
dihydroxyphenylacetic acid,
HVA homovanillic acid, SAL
6,7-dihydroxy-1-methyl-1,2,3,4-
tetrahydroisoquinoline, 1BeTIQ
1-benzyl-1,2,3,4-
tetrahydroisoquinoline, 1MeTIQ
1-methyl-1,2,3,4-
tetrahydroisoquinoline, 3MT 3-
methoxy-4-
hydroxyphenethylamine
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neuroprotection due to his relation to T cell development and
the proliferation (Takeuchi et al. 2006; Fregnan et al. 2012).
High expression of TNFα at the site where neurological dam-
age occurs which suggests that this pro-inflammatory cytokine
is amediator of neuronal injury (Leal et al. 2013).What is more,
glial cells are supposed to release neurotoxic products not only
into the brain parenchyma but also into the rest of the body by
activating the endothelium of blood vessels and recruiting
blood cells to the cerebral parenchyma. It was reported, for
example, that plasma levels of TNFα remained increased even
1 year after intravenous MPTP (N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine, a dopaminergic neurotoxin) administration
in parkinsonian monkeys (Barcia et al. 2005). While CRP is an
acute phase protein released by hepatocytes in response to in-
creases in circulating inflammatory cytokines. Activation of
complement is thought to contribute to the perpetuation of the
inflammatory response and is implicated in neurodegenerative
processes (Bonifati and Kishore 2007). CRP is also thought to
interact with the blood-brain barrier—with increased
paracellular permeability at a high dose that enables its entry
into the central nervous system (CNS) and serves to induce
reactive gliosis and impair CNS function (Hsuchou et al.
2012). According to some authors, CRP is a peripheral bio-
marker that reflects peripheral and central inflammation (and
neuroinflammation) (Felger et al. 2018). Elevated systemic
CRP levels have been noted in numerous conditions associated
with peripheral and central neural damage as well as impaired
neuroprotection, i.e., Alzheimer’s disease (Song et al. 2015;
Kempuraj et al. 2017; Gabin et al. 2018), Parkinson’s disease
(Sawada et al. 2015; Umemura et al. 2015; Qiu et al. 2019),
depression (Felger et al. 2018), opioid use disorder (Wang et al.
2018), or following chimeric antigen receptor T cell (CAR-T)
therapy in cancer (Santomasso et al. 2018; Wang and Han
2018). To justify our choice of markers, it should also be men-
tioned that both TNFα and CRP in serum have been evaluated
in parkinsonian patients and correlated with motor deficits
(Lindqvist et al. 2012; Eidson et al. 2017). In our experiment,
TNFα serum levels but not CRP were only significantly differ-
ent between animals implanted with ALZET osmotic mini-
pumps. TNFα and CRP serum levels of salsolinol-treated rats
were not significantly different from control animals, which
should at least theoretically deny the neuroinflammatory and
neurotoxic properties of (RS)-salsolinol, especially in the pe-
ripheral nervous system. Yet, methodological issues, such as
route of administration, dose, and duration, should be taken into
careful consideration. It needs to be noted that all applied doses
were relatively small in comparison with other published
in vivo experiments (for a summary, see Kurnik-Łucka et al.
2018). It remains unknown whether our results were mediated
peripherally or centrally. We previously reported that (RS)-
salsolinol was not detected (with the limit of detection set at
0.86 ng/l) in serum samples in a similar experimental model,
which might suggest that (RS)-salsolinol did not reach the
systemic blood (Kurnik et al. 2012). However, the blood sam-
ples were collected 24 h after the last delivery, and other related
metabolites were not measured. Lee et al. (2010) demonstrated
that a single administration of (RS)-salsolinol (10μg) by gavage
resulted in a significant elevation of rats’ plasma (RS)-salsolinol
levels, which sharply declined to near basal levels by 14 h. The
mean plasma concentrations of (S)- and (R)-salsolinol at 1 h
after administration were 650 ± 46 and 614 ± 42 pg/ml, respec-
tively. A single intake of 3 g banana (corresponding up to 75μg
of (RS)-salsolinol) also increased the plasma (RS)-salsolinol
concentration. (RS)-salsolinol detected in the brain is likely to
be derived from in situ synthesis [63], but some authors argue
such a hypothesis (Sjöquist and Magnuson 1980; Song et al.
2006). Several authors have also reported that systemically ad-
ministered (RS)-salsolinol is capable of altering behavior
(Antkiewicz-Michaluk et al. 2000; Vetulani et al. 2001), which
indirectly suggests that it could cross the blood-brain barrier.
Yet, in our experiment, we did not observe any behavioral
changes among animals. However, we previously observed
an increase in the percentage of mean residual solid food in
the stomach, suggesting reduced gastric emptying, which re-
mains in agreement with the findings of Banach et al. (2006).
We also reported a decrease in large intestine transit and water
content of fecal matter as well as damage to myenteric neurons
(Kurnik et al. 2015). Dopamine is indeed an important mediator
of gastrointestinal secretion, absorption, and motility and is the
predominant catecholamine neurotransmitter of both central
and peripheral nervous systems. Intrinsic dopaminergic inner-
vation was successfully identified in the bowel of mice and
humans, and is believed to regulate motility and other bowel
functions (Anlauf et al. 2003; Li et al. 2004, 2006). Therefore,
there is a chance that (RS)-salsolinol might affect enteric dopa-
minergic neurotransmission. In vivo, the synthesis of (RS)-
salsolinol was only demonstrated in the central nervous system
(Naoi et al. 2002); however, recently, Villageliú et al. (2018)
demonstrated that in vitro,E. coli can produce (RS)-salsolinol in
the presence of dopamine with production enhanced in the
presence of alcohol. Although this significant discovery needs
an in vivo follow-up to explore whether (RS)-salsolinol produc-
tion is a mechanism by which the microbiota may influence the
host, it has already shed a new light on the (RS)-salsolinol’s
metabolic pathways. Clearly, it is still too early to give a definite
answer with regard to the neurotoxic profile of (RS)-salsolinol.
Unaltered serum levels of TNFα and CRP together with our
behavioral observations suggest that (RS)-salsolinol should not
be neurotoxic in our in vivo model. But still, its potential neu-
roprotective properties need further in vivo examination espe-
cially due to the fact that it can be both delivered exogenously
and synthesized endogenously.
Divergent results of several neuroprotection trials point out
the limitations of transferring results from animal models and
cell cultures to human pathology. It was suggested that only
high concentration of tetrahydroisoquinolines (especially
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(RS)-salsolinol) and prolonged, probably continuous, expo-
sure (endogenous and/or exogenous?) could lead to apoptotic
cell death (DeCuypere et al. 2008; Możdżeń et al. 2015). Yet,
Bettiol et al. (2015) reported that studies with a prospective
design did not support any association between total alcohol
intake and PD risk (with two studies finding an increased risk
with a moderate alcohol consumption), and the case-control
studies were more likely to find protective effects of alcohol
on PD risk. Since (RS)-salsolinol is one of the many
tetrahydroisoquinoline derivatives present in human brain,
thus, it seems reasonable to hypothesize that not the absolute
values but rather specific misbalance among them together
with dopamine precursors and metabolites, possibly due to
genetic and/or environmental instability, might be crucial in
exerting its either neurotoxic and/or neuroprotective role.
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